Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis

Table 1 Characteristics of included randomized controlled trials

Trial	Sample size (n)		mean age (yr)		Regimen		Duration (wk)	Observation time (wk)	Outcome parameters	Jadad scores
	ETV	LAM	ETV	LAM	ETV	LAM
Feng et al[8]	22	25	-	-	0.5 mg/d	100 mg/d	48	4, 12, 24, 36, 48	ACDGI	3
Yang et al[9]	30	30	47.5 ± 9.7		0.5 mg/d	100 mg/d	48	4, 8, 12, 24, 48	ABCI	3
Shen[10]	40	40	46.5	48.5	0.5 mg/d	100 mg/d	48	48	BDEFIJ	3
Huang et al[11]	22	22	48.2	47.5	0.5 mg/d	100 mg/d	52	52	BDEFGHIJ	3
Chen et al[12]	23	24	48.5		0.5 mg/d	100 mg/d	48	24, 48	ACJ	3
Li et al[13]	40	40	51.0		0.5 mg/d	100 mg/d	48	12, 24, 48	ACDEFHI	2
Shao et al[14]	29	28	43.1 ± 10.262	44.11 ± 10.322	0.5 mg/d	100 mg/d	96	12, 24, 36, 48, 60, 72, 84, 96	AHIJ	3
Kong[15]	24	24	47.5		0.5 mg/d	100 mg/d	48	48	BDEFGH	2
Hyun et al[16]	45	41	54 ± 9.4	53.7 ± 12.1	0.5 mg/d	100 mg/d	48	12, 24, 36, 48	ABCHIJ	3
Wang et al[17]	66	64	52.3 ± 15.8	50.8 ± 15.4	0.5 mg/d	100 mg/d	48	12, 24, 36, 48	ABCGHI	2
Yang et al[18]	32	42	47.8 ± 10.2		0.5 mg/d	100 mg/d	48	12, 24, 36, 48	ACDEFI	3
Zhou et al[19]	40	40	46 ± 14		0.5 mg/d	100 mg/d	48	12, 24, 48	BDH	3
Liu et al[20]	30	30	46.04 ± 10.79	45.75 ± 10.26	0.5 mg/d	100 mg/d	48	48	B	3

A: Hepatitis B virus (HBV) DNA undetectability; B: HBV DNA levels; C: Hepatitis B e antigen seroconversion; D: Alanine aminotransferase levels; E: Albumin levels; F: Total bilirubin levels; G: Prothrombin time activity levels; H: Child-Turcotte-Pugh score; I: Drug-resistance; J: Mortality. ETV: Effects of entecavir; LAM: Lamivudine.

Table 2 Sensitivity analysis

Index	Total HBV DNA undetectability
	RR	P value
Removing the inferior quality trials[13,15,17]	1.26 (1.15, 1.39)	< 0.0001
Using random-effect model	1.24 (1.16, 1.33)	< 0.00001
Using fixed-effect model	1.29 (1.22, 1.37)	< 0.00001

HBV: Hepatitis B virus.